TargetMol
![]() |
||
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, specializing in chemical and biological research products and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global small molecule suppliers with over 5000 inhibitors and 80+ compound libraries in stock. TargetMol offers a wide range of high quality research chemicals including novel life-science reagents, inhibitors, activator, APIs and natural compounds for laboratory and scientific use. Website : www.targetmol.com |
![SARS-CoV-2 - Favipiravir - Therapeutic Candidates](https://www.clinisciences.com/es/upload/thumbs/therapeutic-covid-19-aghrup-36c5c7.jpg)
SARS-CoV-2 - Favipiravir - Therapeutic Candidates
Favipiravir, also known as T-705 or Avigan, is a pyrazine-derived antiviral used against RNA viruses. This molecule is an inhibitor of the viral RNA-dependent RNA polymerase. Favipiravir is believed to act selectively on RNA polymerases of viruses and not on those of host cells and it has no action on DNA viruses. Favipiravir would therefore have very few side effects except in pregnant women because it would have a potential for teratogenicity and embryotoxicity in humans. This is why it is currently only marketed in Japan and banned in Europe.
Favipiravir has shown good results against influenza viruses, especially oseltamivir-resistant viruses. A first study, carried out in China, showed that favipiravir could reduce the healing time of Covid-19 from 11 to 4 days for mildly affected patients. Other studies are underway to determine whether favipiravir may be a good candidate for the treatment of Covid-19 caused by CoV-2 SARS.
Resultados de su búsqueda : 6 Producto encontrado
Refine su búsqueda :
RUOCE / IVD
- Biochemicals 6
Referencia
Descripción
Cond.
Precio Sin IVA
‹
›